Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q1 FY19 results · Apr–Jun 2018
Lincoln Pharmaceuticals reported revenue from operations of ₹96.63 crore and net profit of ₹15.60 crore for Q1 FY19 (Apr–Jun 2018), on a standalone basis.
| Item | Q1 FY19 | Q1 FY18 | YoY | Q4 FY18 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 96.63 | — | — | — | — |
| Other income | 2.24 | — | — | — | — |
| Total income | 98.87 | — | — | — | — |
| Profit before tax | 21.95 | — | — | — | — |
| Net profit for the period | 15.60 | — | — | — | — |
| EPS, basic (₹) | 7.80 | — | — | — | — |
| Net margin (%) | 16.1 | — | — |
Standalone
- Filed with BSE
- 20 Aug 2018, 18:17 IST
- Board meeting
- 14 Aug 2018
- Period
- 01 Apr 2018 to 30 Jun 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE